Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The STEP 4 trial [153] (ClinicalTrials.gov identifier: NCT03548987) was a 68-week, randomized, double blind, placebo- controlled trial of once-weekly subcutaneous semaglutide 2.4 mg or placebo for weight management in adults with obesity or overweight with type 2 diabetes
Mild nausea, reduced appetite, and digestive changes may occur initially, but usually settle with gradual dose adjustment and medical supervision
Your PlexusDx provider may also recommend the Precision Peptide Genetic Test ($298) to understand your individual response patterns to medications
National Institute on Aging
US$ 23.30
US$ 29.64
US$ 28.83
US$ 22.52
US$ 24.34
US$ 23.25
US$ 23.39
